Skip to main content
. Author manuscript; available in PMC: 2021 Aug 15.
Published in final edited form as: Clin Cancer Res. 2020 Nov 30;27(4):983–991. doi: 10.1158/1078-0432.CCR-20-3089

Table 3.

Treatment-Related Adverse Events (> 20% of patients)

Adverse Event All Grades Grade 3–5*
n (%) n (%)
Any 31 (91) 18 (53)
Nausea 17 (50) 2 (6)
Diarrhea 12 (35) 7 (21)
Anemia 10 (29) 4 (12)
Neutropenia 10 (29) 6 (18)
Fatigue 9 (26) 0 (0)
Vomiting 7 (21) 0 (0)
Tinnitus 7 (21) 0 (0)
*

1 death occurred from sepsis possibly related to study therapy.